You are here

Drug Discovery

CRT Discovery Laboratories (CRT-DL) is CRT’s in-house drug discovery unit. Based at the Babraham Research Campus, Cambridge, and the London Bioscience Innovation Centre, CRT-DL comprises over 70 staff from both industrial and academic backgrounds. CRT-DL brings together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and its in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients. In recent years, CRT-DL has established successful alliances with AstraZeneca, Teva Pharmaceuticals and FORMA Therapeutics.

Cancer Research UK funds a number of research institutes and drug discovery programmes across the UK and CRT has exclusive commercialisation rights to the wealth of oncology-related discoveries arising from these institutes.

  • CRT Discovery Laboratories

    CRT-DL is a small molecule drug discovery organisation with expertise spanning cancer target validation and disease positioning, assay development and HTS, protein crystallography, medicinal chemistry, PK-PD and cancer models. Through its alliance approach CRT-DL aligns these key skills with internationally competitive academic research and the development capabilities of industry partners to maximise cancer patient benefit.

    This themed approach drives strong partner engagement, teamwork across academia and industry, high quality target selection and efficiency in drug discovery project prosecution. CRT-DL has an impressive track record establishing and executing three major alliances in recent years and, with its industry and academic partners, demonstrating tangible outcomes.

    CRT-DL works with the academic network, potential commercial partners and Cancer Research UK’s Drug Discovery Committee to prioritise areas for evaluation and early portfolio development. Its remit is to deliver first-in-class breakthrough therapies for cancer patients.

    Visit the CRT-DL website

    Related links

  • CRUK Drug Discovery

    Cancer Research UK has an established history of successful drug discovery and development, having contributed to the discovery or clinical trials of nearly 50 drugs now in clinical development.

    Translational research is an expanding part of CRUK's portfolio, reflecting efforts to ensure its research delivers patient benefit. The charity drives specific initiatives to support translational research, including investing more than £20 million in its core drug discovery programmes.


    The CRUK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR CTU). Read more.


    The CRUK Drug Discovery Unit at the Cancer Research UK Manchester Institute. Read more.


    The Beatson Drug Discovery Unit at the Cancer Research UK Beatson Institute. Read more.


     

CRT Discovery Laboratories Open

CRT-DL is a small molecule drug discovery organisation with expertise spanning cancer target validation and disease positioning, assay development and HTS, protein crystallography, medicinal chemistry, PK-PD and cancer models. Through its alliance approach CRT-DL aligns these key skills with internationally competitive academic research and the development capabilities of industry partners to maximise cancer patient benefit.

This themed approach drives strong partner engagement, teamwork across academia and industry, high quality target selection and efficiency in drug discovery project prosecution. CRT-DL has an impressive track record establishing and executing three major alliances in recent years and, with its industry and academic partners, demonstrating tangible outcomes.

CRT-DL works with the academic network, potential commercial partners and Cancer Research UK’s Drug Discovery Committee to prioritise areas for evaluation and early portfolio development. Its remit is to deliver first-in-class breakthrough therapies for cancer patients.

Visit the CRT-DL website

Related links

CRUK Drug Discovery Open

Cancer Research UK has an established history of successful drug discovery and development, having contributed to the discovery or clinical trials of nearly 50 drugs now in clinical development.

Translational research is an expanding part of CRUK's portfolio, reflecting efforts to ensure its research delivers patient benefit. The charity drives specific initiatives to support translational research, including investing more than £20 million in its core drug discovery programmes.


The CRUK Cancer Therapeutics Unit at The Institute of Cancer Research (ICR CTU). Read more.


The CRUK Drug Discovery Unit at the Cancer Research UK Manchester Institute. Read more.


The Beatson Drug Discovery Unit at the Cancer Research UK Beatson Institute. Read more.